NMDP BioTherapies and Cryoport collaborate to Accelerate the Development of Cell and Gene Therapies

NMDP BioTherapies, an organization offering solutions for companies developing and commercializing cell and gene therapies, and Cryoport (NASDAQ: CYRX), a leading global provider of innovative products and services to the fast-growing cell & gene therapy industry enabling the future of medicine for a new era of life sciences, today announced a new strategic partnership. The collaboration will expand the capabilities of IntegriCell™, a standardized bioprocessing, cryopreservation and distribution solution for the global cell therapy market. With cryopreservation facilities in the U.S. and EU, IntegriCell™ is poised to support decentralized and centralized manufacturing models, enabling and accelerating patient access to innovative new therapies. Through this partnership, the companies will provide global bioprocessing and cryopreservation support throughout the U.S. and Europe. The integrated solution combines NMDP BioTherapies’ world-class capabilities for donor identification and collection of high-quality starting material with Cryoport’s cryopreservation, bioprocessing, and industry-leading global logistics capabilities.